Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
AstraZeneca (LSE:AZN) reports positive late-stage results for TAGRISSO plus savolitinib in the SAFFRON Phase III trial in difficult-to-treat NSCLC.
ENHERTU meets key goals in the DESTINY-Lung04 Phase III trial with survival benefits in NSCLC patient groups with limited options.
The company discontinues development of lung cancer candidate volrustomig after trial results show a lack of efficacy.
These moves highlight how fast lung cancer treatment and related technologies are changing, so it can be worth looking at the wider set of companies working at the intersection of healthcare and AI through 6 healthcare AI stocks.
LSE:AZN Earnings & Revenue Growth as at Aug 2026
AstraZeneca is a large GB based pharmaceuticals company with a £183.1b market cap that focuses on discovering, developing, manufacturing and commercialising prescription medicines. Lung cancer sits within its core oncology efforts, so late-stage trial outcomes can materially shape its research priorities and product mix over time.
We’ve flagged 2 risks for AstraZeneca. See which could impact your investment.
How do these lung trial results affect AstraZeneca’s market opportunity?
The TAGRISSO plus savolitinib data from SAFFRON and ENHERTU’s DESTINY-Lung04 outcome both speak to AstraZeneca targeting defined genetic subgroups in non small cell lung cancer where treatment options are limited. That supports a larger addressable lung cancer opportunity across multiple lines of therapy and mechanisms, including EGFR and HER2 driven disease.
Does this news change the AstraZeneca Narrative?
The mixed update largely supports the existing AstraZeneca Narrative, which leans on a strong late stage oncology pipeline but flags execution risk. Positive lung data for TAGRISSO combinations and ENHERTU align with the idea of multiple new high margin oncology products, while the volrustomig discontinuation is an example of the trial setbacks and R&D productivity risk highlighted in that Narrative.
If we take a look at the community Narrative for AstraZeneca, we can see how this news fits into the bigger investment story.
What should investors watch next from AstraZeneca on this story?
The key signposts now are regulatory milestones and label decisions for TAGRISSO plus savolitinib and ENHERTU in NSCLC, along with any disclosed uptake trends or guidance commentary once approvals are granted. Those updates will indicate whether these assets can offset earlier trial disappointments and support the lung cancer contribution to AstraZeneca’s wider oncology plans.
For the full picture including more risks and rewards, check out the complete AstraZeneca analysis.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AZN.L.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com